BackBristol-Myers Squibb Overview
Bristol-Myers Squibb Co.

Bristol-Myers Squibb Target Price

See Bristol-Myers Squibb's analyst price targets ($68) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$63.64

Average Target Price

$68.297.3% upside

7 analysts in the last 4 months

High: $75 | Low: $59

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-10HSBC$652.1% upsideOpen
2026-08-05Roth Capital$7517.9% upsideOpen
2026-08-05Argus ResearchJasper Hellweg$7517.9% upsideOpen
2026-08-04RBC CapitalTrung Huynh$640.6% upsideOpen
2026-07-31Cantor FitzgeraldCarter Gould$597.3% downsideOpen
2026-07-31GuggenheimSeamus Fernandez$7517.9% upsideOpen
2026-07-31Wells Fargo$652.1% upsideOpen
2026-04-08Cantor Fitzgerald$5415.1% downsideOpen
2026-03-06UBSMichael Yee$7010% upsideOpen
2026-02-24RBC CapitalTrung Huynh$605.7% downsideOpen
2026-02-23Piper Sandler$7517.9% upsideOpen
2026-02-19Barclays$7517.9% upsideOpen
2026-02-06Morgan StanleyTerence Flynn$4037.1% downsideOpen
2026-02-06Guggenheim$7213.1% upsideOpen
2026-02-06Wells FargoMohit Bansal$605.7% downsideOpen
2026-01-28Piper Sandler$663.7% upsideOpen
2026-01-13Leerink PartnersDavid Risinger$605.7% downsideOpen
2026-01-09ScotiabankLouise Chen$605.7% downsideOpen
2026-01-07UBS$652.1% upsideOpen
2025-12-12Morgan Stanley$3741.9% downsideOpen
2025-12-12Guggenheim$622.6% downsideOpen
2025-12-10HSBC$5316.7% downsideOpen
2025-12-04ScotiabankLouis Chen$5316.7% downsideOpen
2025-12-03Truist FinancialSrikripa Devarakonda$652.1% upsideOpen
2025-08-05DaiwaNarumi Nakagiri$4234% downsideOpen
2025-07-21Truist FinancialDavid Macdonald$8432% upsideOpen
2025-04-23JefferiesAkash Tewari$686.9% upsideOpen
2025-04-22Piper SandlerDavid Amsellem$652.1% upsideOpen
2024-11-12BMO CapitalEvan Seigerman$614.1% downsideOpen
2024-11-01BMO CapitalEvan David Seigerman$5710.4% downsideOpen
2024-09-23BMO CapitalEvan David Seigerman$4824.6% downsideOpen
2024-07-29Goldman SachsChris Shibutani$5710.4% downsideOpen
2024-07-29BarclaysCarter Gould$4135.6% downsideOpen
2024-07-12UBSTrung Huynh$4332.4% downsideOpen
2024-05-16Cowen & Co.Steve Scala$675.3% upsideOpen
2024-01-30Deutsche BankJames Shin$5513.6% downsideOpen
2023-11-27BMO CapitalEvan Seigerman$605.7% downsideOpen
2023-10-12Leerink PartnersDavid Risinger$663.7% upsideOpen
2023-09-06Cantor FitzgeraldLouise Chen$7517.9% upsideOpen
2022-05-18Wells FargoMohit Bansal$7010% upsideOpen
2022-05-02BMO Capital$9244.6% upsideOpen
2022-05-02Barclays$686.9% upsideOpen
2022-05-02GuggenheimSeamus Fernandez$8025.7% upsideOpen
2022-05-02BMO CapitalEvan Seigerman$8736.7% upsideOpen
2022-04-11Morgan StanleyTerence Flynn$640.6% upsideOpen
2022-04-04BMO CapitalEvan Seigerman$8127.3% upsideOpen
2022-03-28Morgan StanleyMatthew Harrison$663.7% upsideOpen
2022-03-17BMO CapitalEvan David Seigerman$7416.3% upsideOpen
2021-10-28BarclaysCarter Gould$663.7% upsideOpen
2021-10-25CitigroupAndrew Baum$7517.9% upsideOpen

Bristol-Myers Squibb (BMY) FAQ

As of the most recent data, BMY shows a target price of $68. Scroll down for historical charts and peer comparison views.

If Bristol-Myers Squibb moved to the average analyst target of $68, shares would be roughly 7.3% higher than $63.64. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Bristol-Myers Squibb's earnings trajectory.

Besides this target price page, Stockcircle has Bristol-Myers Squibb's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $68) with ownership activity and broader fundamentals.

Bristol-Myers Squibb's target price is $68; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.